Physician

Raphael Bosse, MD

According to 2025 Medicare claims, Raphael Bosse, MD (NPI: 1962933325) practices medical oncology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34102-5451.

Bosse's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 964 traditional Medicare patients, billed 118,848 HCPCS/CPT codes, and received $1,510,868 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 583 prescription claims across 153 beneficiaries totaling $1,835,243 in drug costs, led by Revlimid (Lenalidomide). Open Payments data shows 148 records totaling $3,450. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $618 to $1,835,243. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$755K$1.5M2023 Medicare payment: $163,791 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,510,868 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
2022N/RN/RN/R
202333429,182$163,791
2024964118,848$1,510,868

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$918K$1.8M2020 Drug cost: $618 (USD; Tot_Drug_Cst)2021 Drug cost: $1,483 (USD; Tot_Drug_Cst)2022 Drug cost: $2,722 (USD; Tot_Drug_Cst)2023 Drug cost: $41,880 (USD; Tot_Drug_Cst)2024 Drug cost: $1,835,243 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
20201431$618
20211229$1,483
20221622$2,722
20232858$41,880
2024153583$1,835,243

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more204281$100
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more207314$71
96372Injection of drug or substance under skin or into muscle185356$11
36415Insertion of needle into vein for collection of blood sample6081,217$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count5621,165$8

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
RevlimidLenalidomide36945$594,431
TagrissoOsimertinib Mesylate13390$222,360
JakafiRuxolitinib Phosphate12360$208,104
XtandiEnzalutamide11330$159,523
EliquisApixaban342,039$38,859

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.148$3,450Merck Sharp & Dohme LLC
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Raphael Bosse, MD?

Tedicare shows public-source Medicare data for Raphael Bosse, MD (NPI 1962933325), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Raphael Bosse, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Raphael Bosse, MD?

Raphael Bosse, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Raphael Bosse, MD have Open Payments data?

Raphael Bosse, MD has 148 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.